$RARE
Ultragenyx Pharmaceutical Inc.

2018 Q1 Form 10-Q Financial Statement

#000156459018011341 Filed on May 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q1
Revenue $10.68M $0.00
YoY Change
Cost Of Revenue $225.0K
YoY Change
Gross Profit $10.45M
YoY Change
Gross Profit Margin 97.89%
Selling, General & Admin $31.44M $18.69M
YoY Change 68.19% 41.48%
% of Gross Profit 300.76%
Research & Development $75.50M $51.27M
YoY Change 47.26% 26.86%
% of Gross Profit 722.35%
Depreciation & Amortization $6.160M $1.161M
YoY Change 430.58% 113.42%
% of Gross Profit 58.94%
Operating Expenses $107.2M $69.95M
YoY Change 53.19% 30.46%
Operating Profit -$96.71M
YoY Change
Interest Expense $1.740M $1.080M
YoY Change 61.11% 10.2%
% of Operating Profit
Other Income/Expense, Net -$4.960M $580.0K
YoY Change -955.17% -32.95%
Pretax Income $30.29M -$68.29M
YoY Change -144.36% 29.44%
Income Tax $39.00K
% Of Pretax Income 0.13%
Net Earnings $30.25M -$68.29M
YoY Change -144.3% 29.44%
Net Earnings / Revenue 283.35%
Basic Earnings Per Share $0.63
Diluted Earnings Per Share $0.62 -$1.632M
COMMON SHARES
Basic Shares Outstanding 48.19M 41.73M
Diluted Shares Outstanding 49.08M

Balance Sheet

Concept 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $541.3M $425.2M
YoY Change 27.3% 3.23%
Cash & Equivalents $229.2M $159.5M
Short-Term Investments $314.6M $265.7M
Other Short-Term Assets $34.50M $19.50M
YoY Change 76.92% 5.98%
Inventory $2.100M
Prepaid Expenses
Receivables $3.700M
Other Receivables $0.00
Total Short-Term Assets $581.6M $444.7M
YoY Change 30.78% 3.37%
LONG-TERM ASSETS
Property, Plant & Equipment $20.80M $16.50M
YoY Change 26.06% 23.13%
Goodwill $44.41M
YoY Change
Intangibles $137.1M
YoY Change
Long-Term Investments $29.90M $80.90M
YoY Change -63.04% 6.59%
Other Assets $3.500M $3.800M
YoY Change -7.89% -17.39%
Total Long-Term Assets $235.8M $101.1M
YoY Change 133.23% 7.55%
TOTAL ASSETS
Total Short-Term Assets $581.6M $444.7M
Total Long-Term Assets $235.8M $101.1M
Total Assets $817.4M $545.8M
YoY Change 49.76% 4.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.600M $8.300M
YoY Change -8.43% 38.33%
Accrued Expenses $49.30M $42.80M
YoY Change 15.19% 81.36%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $57.60M $51.80M
YoY Change 11.2% 73.24%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.900M $5.600M
YoY Change -12.5% 25.0%
Total Long-Term Liabilities $4.900M $5.600M
YoY Change -12.5% 25.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $57.60M $51.80M
Total Long-Term Liabilities $4.900M $5.600M
Total Liabilities $93.70M $57.30M
YoY Change 63.53% 66.76%
SHAREHOLDERS EQUITY
Retained Earnings -$802.4M
YoY Change
Common Stock $50.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $723.7M $488.5M
YoY Change
Total Liabilities & Shareholders Equity $817.4M $545.8M
YoY Change 49.75% 4.12%

Cashflow Statement

Concept 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income $30.25M -$68.29M
YoY Change -144.3% 29.44%
Depreciation, Depletion And Amortization $6.160M $1.161M
YoY Change 430.58% 113.42%
Cash From Operating Activities -$89.48M -$61.21M
YoY Change 46.18% 36.33%
INVESTING ACTIVITIES
Capital Expenditures $475.0K $485.0K
YoY Change -2.06% -67.16%
Acquisitions
YoY Change
Other Investing Activities -$70.55M -$10.14M
YoY Change 595.76% -143.61%
Cash From Investing Activities -$71.03M -$10.62M
YoY Change 568.81% -148.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $271.0M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 286.4M 68.97M
YoY Change 315.28% 22148.39%
NET CHANGE
Cash From Operating Activities -89.48M -61.21M
Cash From Investing Activities -71.03M -10.62M
Cash From Financing Activities 286.4M 68.97M
Net Change In Cash 126.2M -2.839M
YoY Change -4543.89% -87.55%
FREE CASH FLOW
Cash From Operating Activities -$89.48M -$61.21M
Capital Expenditures $475.0K $485.0K
Free Cash Flow -$89.95M -$61.70M
YoY Change 45.8% 33.03%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 us-gaap Long Term Investments
LongTermInvestments
29907000
CY2018Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
137122000
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
141545000
CY2018Q1 us-gaap Goodwill
Goodwill
44406000
CY2018Q1 us-gaap Sales Revenue Net
SalesRevenueNet
10677000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-71028000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-10620000
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
270969000
CY2018Q1 rare Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
11808000
CY2018Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
225000
CY2017Q1 rare Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
67591000
CY2018Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
3642000
CY2017Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1378000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
286419000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
68969000
CY2018Q1 us-gaap Effect Of Exchange Rate On Cash Continuing Operations
EffectOfExchangeRateOnCashContinuingOperations
249000
CY2017Q1 us-gaap Effect Of Exchange Rate On Cash Continuing Operations
EffectOfExchangeRateOnCashContinuingOperations
17000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
126162000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2839000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
103041000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
164607000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229203000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
161768000
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.63
CY2018Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.62
CY2018Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48190511
CY2018Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49077742
CY2018Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-289000
CY2018Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
-5272000
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4734000
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
18797000
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
50000
CY2018Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1526972000
CY2018Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-946000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
14499000
CY2018Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-239000
CY2017Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
549000
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6160000
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1161000
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-802419000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
723657000
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
817350000
CY2018Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-4773000
CY2017Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
648000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5063000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-930000
CY2018Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
259000
CY2017Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-75000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49665203
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1317000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2989000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-12583000
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-12470000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-89478000
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49665203
CY2018Q1 rare Collaboration And License Revenue
CollaborationAndLicenseRevenue
9362000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-61205000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
475000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
485000
CY2018Q1 us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
130000000
CY2018Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
260830000
CY2017Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
87527000
CY2017Q1 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
12415000
CY2018Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
60277000
CY2017Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
64977000
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:13pt;margin-top:4pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The accompanying consolidated financial statements have been prepared in accordance with GAAP. The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to sales return reserves, clinical trial accruals, fair value of assets and liabilities, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. </p></div>
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159501000
CY2017Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
271000
CY2017Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1996000
CY2018Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
529462000
CY2018Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
631000
CY2018Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
528831000
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
224029000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
380000
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
223649000
CY2018Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2018Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
1808000
CY2017Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
737000
CY2018Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
260000
CY2017Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
20000
CY2017Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
5986000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8092000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18797000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14499000
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5150737
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5478008
CY2018Q1 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-315000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-5298000
CY2018Q1 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-631000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-382000
CY2018Q1 us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
130000000

Files In Submission

Name View Source Status
0001564590-18-011341-index-headers.html Edgar Link pending
0001564590-18-011341-index.html Edgar Link pending
0001564590-18-011341.txt Edgar Link pending
0001564590-18-011341-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201805071934472381753.jpg Edgar Link pending
g201805071935024741492.jpg Edgar Link pending
g201805071935025191492.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rare-10q_20180331.htm Edgar Link pending
rare-20180331.xml Edgar Link completed
rare-20180331.xsd Edgar Link pending
rare-20180331_cal.xml Edgar Link unprocessable
rare-20180331_def.xml Edgar Link unprocessable
rare-20180331_lab.xml Edgar Link unprocessable
rare-20180331_pre.xml Edgar Link unprocessable
rare-ex106_201.htm Edgar Link pending
rare-ex311_6.htm Edgar Link pending
rare-ex312_8.htm Edgar Link pending
rare-ex321_7.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending